George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.
George Simon, MD, FACP, FCCP, chair, Department of Medical Oncology, Advent Health, department chair, Medical Oncology, Moffit Cancer Center, discusses the evaluation of datopotamab deruxtecan (DS-1062) in TROP-2–overexpressing solid tumors.
The phase 1 TROPION-PanTumor01 trial (NCT03401385) evaluated the safety and tolerability of the TROP-2–targeting antibody-drug conjugate (ADC), datopotamab deruxtecan.
The goal of the study was to understand how TROP-2–overexpressing solid tumors reacted to datopotamab deruxtecan, Simon adds.
The trial served as a preliminary step before ADC is evaluated in combination with other therapies and against the current standard of care, Simon continues. The phase 1 study will inform a more detailed portfolio of studies that will come down the line, Simon concludes.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive(R).